Gritstone Bio (Gritstone Bio) FCF Margin % : -67,927.59% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Gritstone Bio FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Gritstone Bio's Free Cash Flow for the three months ended in Dec. 2023 was $-19.70 Mil. Gritstone Bio's Revenue for the three months ended in Dec. 2023 was $0.03 Mil. Therefore, Gritstone Bio's FCF Margin % for the quarter that ended in Dec. 2023 was -67,927.59%.

As of today, Gritstone Bio's current FCF Yield % is -144.95%.

The historical rank and industry rank for Gritstone Bio's FCF Margin % or its related term are showing as below:

GRTS' s FCF Margin % Range Over the Past 10 Years
Min: -9483.1 Med: -2496.67 Max: -120.17
Current: -9475.98

During the past 8 years, the highest FCF Margin % of Gritstone Bio was -120.17%. The lowest was -9483.10%. And the median was -2496.67%.

GRTS's FCF Margin % is ranked worse than
91.77% of 1033 companies
in the Biotechnology industry
Industry Median: -148.24 vs GRTS: -9475.98

Gritstone Bio FCF Margin % Historical Data

The historical data trend for Gritstone Bio's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gritstone Bio FCF Margin % Chart

Gritstone Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-2,318.08

-2,675.25

-120.17

-1,314.25

-9,483.10

Gritstone Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-2,400.68	-7,685.79	-8,171.00	-8,914.13	-67,927.59

Competitive Comparison of Gritstone Bio's FCF Margin %

For the Biotechnology subindustry, Gritstone Bio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gritstone Bio's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gritstone Bio's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Gritstone Bio's FCF Margin % falls into.

Gritstone Bio FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Gritstone Bio's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-126.22	/	1.331
	=	-9,483.10 %

Gritstone Bio's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-19.699	/	0.029
	=	-67,927.59 %

Gritstone Bio FCF Margin % Related Terms

Thank you for viewing the detailed overview of Gritstone Bio's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Gritstone Bio (Gritstone Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gritstone Bio Inc (NAS:GRTS) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

2JQ:Germany 2JQ:Germany

Address

5959 Horton Street, Suite 300, Emeryville, CA, USA, 94608

Website

https://gritstonebio.com

Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, BiSAb, among others.

Executives

Lawrence Corey	director	C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Naiyer Rizvi	director	C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Elaine V Jones	director	C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Clare Fisher	director	C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Steve E. Krognes	director	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Shefali Agarwal	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Vassiliki Economides	officer: See Remarks	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Erin Jones	officer: See Remarks	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
James Cho	officer: Chief Accounting Officer	C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Raphael Rousseau	officer: See Remarks	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Roman Yelensky	officer: See Remarks	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Thomas Woiwode	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Rahsaan Thompson	officer: EVP and General Counsel	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Vijay Yabannavar	officer: See Remarks	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Nicholas Simon	director	101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142